Abstract

Endometrial cancer remains a significant cause of morbidity among women worldwide, with advanced-stage disease posing therapeutic challenges. This article explores recent advances in targeted therapies, focusing on molecular pathways such as PI3K/AKT/mTOR and immune checkpoint inhibitors. We review clinical trial data, discuss treatment efficacy, and highlight future directions. Results indicate improved progression-free survival with targeted agents, though challenges like resistance persist. This comprehensive analysis underscores the potential of personalized medicine in improving outcomes for endometrial cancer patients.